-
-
Pharma & Human Health -
Finance -
Pharma & Human Health -
Pharma & Human Health
Editor’s Choice
Editor's Choice
AnonyMine: a platform enabling anonymisation and simulation of microbiome and clinical data
Reusing data collected in clinical studies is of strong scientific and economic interest. Anonymisation has emerged as a solution to extend data life, while providing regulatory compliance and privacy protection. Nevertheless, true anonymisation of complex […]
Editor's Choice
Ferring v Finch: Ripples from the Decision
Three patent claims, one present in each of three US patents held by the Finch Therapeutics Group Inc. (Finch), have been found to have been infringed by Ferring Pharmaceuticals Inc.’s (Ferring) activities in the US […]
Editor's Choice
Eligo Publishes a Landmark Study in Nature That Unlocks Genome Editing of Bacteria in the Gut
Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, publishes a landmark study in Nature that unlocks Genome Editing of Bacteria in the Gut. […]
In Case you Missed it:
Finance
Viome Raises $25M To Launch Diagnostic Division
Viome, a pioneer in microbiome health science and personalized health solutions, today announced a $25 million internal Series D with participation from Khosla Ventures, Bold Capital WRG Ventures, Marc Benioff, and more. This continued support from existing backers […]
Finance
Lallemand inaugurates new research and development laboratories
Lallemand announces the inauguration of its new laboratories in France, increasing its capacity by over 800 square meters. This significant expansion enhances its interdisciplinary research and development capabilities at the Blagnac and Beauzelle sites. The […]
Finance
IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality
Infant Bacterial Therapeutics has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company’s drug candidate IBP-9414, a bacterial strain found […]
Finance
ZBiotics Raises $12M Series A to bring genetically engineered probiotic products to market
ZBiotics, the pioneers carving a new category of genetically engineered probiotics, today announced the close of its $12M Series A funding round, led by Spring Tide Capital. The oversubscribed round also includes participation by Access Capital, Seamless Capital, Goat […]
Pharma & Human Health
Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus
The novel active agent HY-133, which was developed by HYpharm and prepared for clinical trials in collaboration with the German Center for Infection Research (DZIF) and universities in Tübingen, Munich, Münster and Greifswald, received approval […]
Pharma & Human Health
A virally-encoded tRNA neutralizes the PARIS antiviral defense system
Scientists at Montana State University have been studying unique immune systems for decades, and a research team in the Department of Microbiology and Cell Biology took another step forward with work described in a paper published […]
Pharma & Human Health
Revealing the mysteries within microbial genomes
A new technique developed at Lawrence Berkeley National Laboratory (Berkeley Lab) will make it much easier for researchers to discover the traits or activities encoded by genes of unknown function in microbes, a key step […]
Pharma & Human Health
Morinaga Milk Obtains the Registration of “New Food Ingredient” in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods
Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found […]
